share_log

United Therapeutics | 10-Q: Q2 2024 Earnings Report

United Therapeutics | 10-Q: Q2 2024 Earnings Report

美国联合医疗 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/31 18:34

Moomoo AI 已提取核心信息

United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
美国联合医疗报告了强劲的2024年第二季度财务结果，总收入增长20%，达到71490万，主要得益于Tyvaso产品销售的强劲增长。包括Tyvaso DPI和雾化Tyvaso在内的Tyvaso总收入同比增长25%，达到39820万，受益于患者的增加和价格上涨。尽管营业费用增加，营业收入仍然保持稳定，在2023年第二季度为31340万，而2024年第二季度为31990万。研究和开发费用增加了57%，达到13960万，而销售、一般和管理费用上升了37%，达到17760万，主要是由于法律费用和人事成本的增加。截至2024年6月30日，公司保持了强劲的财务状况，现金和投资总额达到43亿。在本季度期间，美国联合医疗实施了一项10亿的加速股份回购计划，并将其信贷设施余额减少至50000万。公司继续推进其管道，包括针对IPF和PPF适应症的雾化Tyvaso的第三阶段试验，以及器官制造的举措。
美国联合医疗报告了强劲的2024年第二季度财务结果，总收入增长20%，达到71490万，主要得益于Tyvaso产品销售的强劲增长。包括Tyvaso DPI和雾化Tyvaso在内的Tyvaso总收入同比增长25%，达到39820万，受益于患者的增加和价格上涨。尽管营业费用增加，营业收入仍然保持稳定，在2023年第二季度为31340万，而2024年第二季度为31990万。研究和开发费用增加了57%，达到13960万，而销售、一般和管理费用上升了37%，达到17760万，主要是由于法律费用和人事成本的增加。截至2024年6月30日，公司保持了强劲的财务状况，现金和投资总额达到43亿。在本季度期间，美国联合医疗实施了一项10亿的加速股份回购计划，并将其信贷设施余额减少至50000万。公司继续推进其管道，包括针对IPF和PPF适应症的雾化Tyvaso的第三阶段试验，以及器官制造的举措。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日